US Stocks Move: Novo Nordisk (NVO.US) drops nearly 10% as new heart disease drug trial fails to meet primary endpoint

```htmlAccording to Golden Ten Data APP, on Friday, Danish pharmaceutical giant Novo Nordisk (NVO.US) opened with a sharp decline, and as of press time, the drop approached 10%. In the news, the company announced that its highly anticipated cardiovascular new drug ziltivekimab failed to reach the primary endpoint in a major late-stage clinical trial. The drug did not significantly reduce the incidence of major adverse cardiovascular events (MACE) compared to placebo. This setback in the key trial is undoubtedly another blow to the Danish pharmaceutical company. The company is making every effort to restore investors’ confidence in its research pipeline and execution capabilities, especially in the challenging US market.```